212 - Epidemiology of RSV and Prevention Measures

Saturday, October 14, 2023

10:30 AM – 11:45 AM US ET

Location: Ballroom (Third Floor)

All relevant financial disclosures have been mitigated.

Moderator(s)

Natasha Halasa, MD, MPH (she/her/hers)

Craig Weaver Professor of Pediatrics
Division of Pediatric Infectious Diseases
Vanderbilt University Medical Center
Nashville, TN, United States
Eric A. F. Simões, MD, M.B., B.S., DCH

Professor
Children's Hospital Colorado
Denver, CO, United States

Faculty(s)

Meredith McMorrow, MD, MPH (she/her/hers)

Acting Branch Chief
Respiratory Viruses Branch
CDC/NCIRD/CORVD/SPB
Atlanta, GA, United States

Slides
Michael Melgar, MD (he/him/his)

Medical Epidemiologist
Centers for Disease Control and Prevention
Atlanta, GA, United States

Slides
Angela Branche, MD

Associate Professor of Medicine
Medicine
University of Rochester
Rochester, NY, United States

Slides

Disclosure(s):

Natasha B. Halasa, MD, MPH: Merck and Company, Inc.: Grant/Research Support (Ongoing)

Eric A. F. Simões, MD, M.B., B.S., DCH: AbbVie Inc: DSMB (Ongoing); AstraZenca: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Travel (Ongoing); GSK: Advisor/Consultant (Ongoing), DSMB (Ongoing); Janssen Pharmaceuticals, a Johnson & Johnson Company: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Merck and Company, Inc.: Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Travel for meetings (Ongoing); Regeneron, Inc: Grant/Research Support (Ongoing); Sanofi: Advisor/Consultant (Ongoing); Shinogi: Advisor/Consultant (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-23-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the RSV epidemiology in pediatrics;
describe the RSV epidemiology in adults;
explain current and upcoming prevention measures for RSV

Presentations:

10:30 AM – 10:55 AM US ET

Pediatric RSV Epidemiology Before, During and After the COVID-19 Pandemic
Speaker: Meredith L. McMorrow, MD, MPH (she/her/hers) – CDC/NCIRD/CORVD/SPB
10:55 AM – 11:20 AM US ET

The Current and Upcoming Prevention Products for RSV
Speaker: Michael Melgar, MD (he/him/his) – Centers for Disease Control and Prevention
11:20 AM – 11:45 AM US ET

RSV in Adult Populations: Gains and Gaps in Our Understanding of Disease Burden
Speaker: Angela R. Branche, MD – University of Rochester